Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Apogee Therapeutics, Inc.NASDAQ: APGE
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $85.85M (cash outflow) rose 29.9% year over year, ahead of the +23.9% change in trailing-twelve-month net income. Sequentially, it rose 15.8% from the prior quarter. Over 3 fiscal years it compounded at +86.0% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 11 analysts of -$273.82M (+7.0%) for the fiscal year ending Dec 2026, a slowdown from the +40.5% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$85.85M+15.8% QoQ
- Last fiscal yearDec 2025
- -$255.84M+40.5% YoY
- LTMJun 2026
- -$294.37M+23.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +29.9% | +20.0% | -9.9 pp |
| 1 year | +40.5% | +7.0% | -33.4 pp |
| 3-year CAGR | +86.0% | +22.2% | -63.8 pp |
| 5-year CAGR | -22.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (255.84M) USD
- Year-over-year change
- -40.5%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (255.84M) | -40.5% |
| FY2024 | 2024-12-31 | (182.15M) | -116.9% |
| FY2023 | 2023-12-31 | (83.99M) | -111.1% |
| FY2022 | 2022-12-31 | (39.79M) | — |
Net Income vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +23.9% is the 6th highest of 10, against a peer median of +34.2%.
- Over three fiscal years its annual growth of +86.0% compares with a peer median of +11.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥1.24B CNY | +212.7% | +11.7% | 221.3% |
| LTM Mar 2026 | $608.92M USD | +10.8% | -6.7% | 91.0% | |
| LTM Sep 2026 | $428.73M USD | +40.0% | +40.3% | — | |
| LTM Jun 2026 | $294.37M USD | +23.9% | +86.0% | — | |
| LTM Mar 2026 | $250.64M USD | +12.0% | -3.0% | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $243.1M USD | +34.2% | +65.5% | — |
| LTM Sep 2026 | $237.46M USD | +56.8% | +65.6% | 3851.1% | |
| LTM Jun 2026 | $226.48M USD | +52.3% | +63.7% | — | |
| LTM Jun 2026 | $188.21M USD | -11.4% | -26.6% | 41.9% | |
| LTM Sep 2026 | $2.81M USD | -98.7% | -12.6% | 0.2% | |
| Peer median (excluding APGE) | — | +34.2% | +11.7% | 91.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Depreciation & Amortization | 0 | 0 | 189K | 1.42M |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.14M | 6.1M | 23.33M | 46.28M |
| Change in Working Capital | 9.82M | 6.11M | (2M) | (15.48M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 418K | 1.61M | (1.07M) | 150K |
| Other Working Capital | 9.4M | 4.49M | (930K) | (15.63M) |
| Other Non-Cash Items | 11.4M | (2.98M) | (10.55M) | (3.82M) |
| Operating Cash Flow | (16.43M) | (74.76M) | (171.17M) | (227.45M) |
| Capital Expenditures | 0 | (167K) | (1.15M) | (5.15M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (303.74M) | (649.45M) | (642.3M) |
| Sales of Investments | 0 | 30M | 350.14M | 467.87M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (273.91M) | (300.46M) | (179.57M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 168.32M | 315.39M | 493.48M | 396.49M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 1.63M | 0 |
| Financing Cash Flow | 168.32M | 315.39M | 495.11M | 396.49M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 151.89M | (33.28M) | 23.47M | (10.53M) |
| Free Cash Flow | (16.43M) | (74.93M) | (172.33M) | (232.6M) |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.